Medicinal Mushrooms (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (06/09/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Introduction

Added text to state that clinical trials in cancer patients have demonstrated that Ganoderma lucidum products are generally well tolerated (cited Jin et al. as reference 1).

Reishi (Ganoderma lucidum)

Added this new section.

This summary is written and maintained by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Reishi (Ganoderma lucidum)

Next section >
About This PDQ Summary

Mushrooms (PDQ®)—Health Professional Version - National Cancer Institute